BCG Treatment for Bladder Cancer: How It Works and What to Expect

Medical Conditions · By Web Admin · · Updated · 11 min read
BCG Treatment for Bladder Cancer: How It Works and What to Expect

If you or a loved one has been diagnosed with non-muscle-invasive bladder cancer, your urologist has likely discussed BCG treatment for bladder cancer as a key part of the treatment plan. BCG (Bacillus Calmette-Guerin) treatment for bladder cancer is a form of immunotherapy that has been a cornerstone of care for preventing recurrence and progression of early-stage bladder cancer for decades. This article is independent, educational information and is not medical advice — your urologist and oncology team direct your treatment.

BCG is a live, weakened form of the bacterium Mycobacterium bovis, originally developed as a tuberculosis vaccine. When instilled directly into the bladder, it triggers an immune response that helps the body target residual cancer cells. Major cancer authorities, including the American Cancer Society and the National Cancer Institute, describe BCG as a highly effective intravesical (inside-the-bladder) therapy for non-muscle-invasive bladder cancer, with a well-documented ability to reduce both recurrence and progression to more advanced disease. For a broader understanding of bladder cancer, including early warning signs, read our article on symptoms of bladder cancer. You can also explore our conditions guide for more on related conditions.

How BCG Treatment Works

BCG immunotherapy works differently from chemotherapy. Rather than directly killing cancer cells, BCG stimulates your own immune system to recognize and attack them. Here is how the process works at a biological level:

Stay ahead in healthcareThe latest happenings in the medical field — free, about monthly, no spam.
  1. BCG bacteria attach to the bladder wall: After being instilled into the bladder through a catheter, the BCG binds to the urothelial lining, particularly in areas where cancer cells are present or where tissue has been disrupted by surgery.
  2. Immune cells are recruited: The presence of foreign bacteria triggers an immune response. White blood cells, including T cells, natural killer cells, and macrophages, flood into the bladder wall.
  3. Cancer cells are targeted: The activated immune cells attack both the BCG bacteria and the nearby cancer cells, creating a localized inflammatory environment that is hostile to tumor survival.
  4. Immune memory develops: Over the course of treatment, the immune system builds a sustained response against bladder cancer cells, providing ongoing protection against recurrence.

This immune-mediated mechanism is why BCG is classified as immunotherapy and why it has remained a mainstay of bladder cancer treatment since it was first used for this purpose in the late 1970s.

Who Is a Candidate for BCG Treatment?

BCG treatment is recommended for specific stages and grades of bladder cancer. According to guidelines from the American Urological Association (AUA) and the Society of Urologic Oncology (SUO), BCG is generally indicated for:

  • High-grade non-muscle-invasive bladder cancer (NMIBC): Including high-grade Ta and T1 tumors.
  • Carcinoma in situ (CIS): A flat, high-grade cancer that lines the bladder surface. BCG is considered a primary treatment for CIS.
  • Intermediate-risk NMIBC: In patients with recurrent or multiple low-grade tumors, BCG may be recommended as an alternative to intravesical chemotherapy.

BCG is not appropriate for muscle-invasive bladder cancer (T2 and beyond), which typically requires more aggressive treatment such as radical cystectomy, systemic chemotherapy, or radiation. It is also generally not used for a single, small, low-grade Ta tumor, which has a low risk of progression. Your urologist determines whether BCG is right for your specific tumor type, grade, and risk category.

What to Expect During BCG Treatment

Understanding the general treatment approach can help ease anxiety about the process. BCG treatment for bladder cancer is typically given in two phases, and your urologist sets and adjusts the exact schedule for you.

Induction Phase

The induction course commonly consists of a series of weekly instillations, often beginning a few weeks after the transurethral resection of bladder tumor (TURBT) surgery. Each treatment session generally follows a similar pattern:

  1. A thin catheter is inserted into the bladder through the urethra.
  2. The BCG solution is slowly instilled into the bladder through the catheter.
  3. The catheter is removed.
  4. You are asked to hold the solution in your bladder for a period of time (often around 2 hours), changing positions periodically so the solution contacts all surfaces of the bladder.
  5. Afterward, you urinate to expel the solution.

The in-office procedure itself is usually brief — often about 15 to 20 minutes — not including the retention period. Most patients can resume normal activities the same day, though some experience fatigue or urinary symptoms afterward. Your care team will give you specific instructions for your situation.

Maintenance Phase

After completing induction, maintenance BCG is important for long-term cancer control. A widely used maintenance approach, based on work by the Southwest Oncology Group (SWOG), spreads additional short courses of BCG over a period of up to three years. Research shows that maintenance BCG can meaningfully reduce the risk of recurrence compared with induction alone. Because supply, tolerance, and individual response vary, your urologist decides the specific maintenance schedule and may modify it over time.

BCG Supply and the Ongoing Shortage

An important practical issue to understand is that BCG supply has been constrained for years. There has been a limited number of manufacturers producing BCG for bladder cancer, and demand has at times exceeded supply, creating a well-documented, ongoing shortage. Manufacturers have publicly worked to expand production capacity, but availability can still fluctuate.

When BCG is in short supply, urologists and professional societies have used strategies such as prioritizing patients at the highest risk, sometimes splitting doses among patients, and reserving BCG for the indications where it provides the most benefit. If your treatment plan is affected by supply, your care team can explain the current situation and discuss alternatives. This is a fast-changing area, so ask your urologist about the latest availability rather than relying on older figures.

Side Effects of BCG Treatment

Because BCG involves instilling live bacteria into the bladder, side effects are common and are often a sign that the immune system is responding. Most side effects are temporary and manageable:

Common Side Effects (Affecting Many Patients)

  • Urinary frequency and urgency: The need to urinate more often and with greater urgency, typically in the day or two after each treatment.
  • Dysuria: Burning or discomfort during urination.
  • Hematuria: Some blood in the urine, which may appear pink or red.
  • Flu-like symptoms: Low-grade fever, chills, fatigue, and body aches lasting a day or two.
  • Bladder irritation: General discomfort in the lower abdomen.

Less Common but Serious Side Effects

  • Systemic BCG infection (BCGosis or BCG sepsis): In rare cases, BCG can spread beyond the bladder and cause a body-wide infection. Signs can include a high or persistent fever, severe malaise, shaking chills, or signs of infection in other organs. This is a medical emergency and requires urgent treatment, which may include anti-tuberculosis medications directed by your physicians.
  • Granulomatous prostatitis: BCG can cause inflammation in the prostate gland in men.
  • Allergic-type reactions: Rash, joint pain, or other reactions can occur.
  • Reduced bladder capacity: Repeated BCG treatment can occasionally lead to a decrease in bladder capacity over time.
Seek urgent care and contact your urologist right away if you have:
  • A high fever, or any fever that persists (your care team will give you a specific temperature threshold and time frame to watch for — commonly a fever at or above about 101.3°F / 38.5°C that does not quickly resolve).
  • Shaking chills, severe fatigue, confusion, or other signs of a body-wide (systemic) infection.
  • Blood in the urine that is heavy, worsening, or beyond what your team told you to expect, or clots you cannot pass.
  • Inability to urinate, severe pelvic or abdominal pain, or symptoms that feel severe or unusual.

If you have symptoms of a life-threatening emergency, call 911 (in the U.S.) or go to the nearest emergency department. When in doubt, contact your care team — do not wait.

Effectiveness and Realistic Expectations

BCG has long been one of the most effective treatments for non-muscle-invasive bladder cancer. Cancer authorities including the American Cancer Society and the National Cancer Institute report that BCG can produce durable responses in many patients, that it reduces the likelihood of recurrence, and that it lowers the risk of progression to muscle-invasive disease compared with surgery (TURBT) alone. For carcinoma in situ, a substantial share of patients achieve a complete response after adequate BCG therapy.

At the same time, it is important to have realistic expectations. A meaningful proportion of patients will experience recurrence despite BCG, and some will develop what is called BCG-unresponsive disease, in which the cancer persists or comes back despite adequate treatment. Because bladder cancer can recur years later, ongoing surveillance is essential even after a good initial response. Your care team tracks your response and adjusts the plan accordingly, so treat exact percentages you read online as general context rather than a prediction of your individual outcome.

What Happens If BCG Does Not Work?

If bladder cancer recurs or persists after adequate BCG therapy (BCG-unresponsive disease), the options have expanded in recent years, which is genuinely encouraging news. Depending on your situation, your urologist and oncologist may discuss:

  • Radical cystectomy: Surgical removal of the bladder, which remains a standard option for BCG-unresponsive high-risk disease and can be curative for many patients.
  • Immunotherapy: Pembrolizumab (Keytruda), a systemic immune checkpoint inhibitor, is FDA-approved for certain patients with BCG-unresponsive, high-risk NMIBC who are not undergoing or not candidates for cystectomy.
  • Gene therapy: Nadofaragene firadenovec (Adstiladrin), an intravesical gene therapy, is FDA-approved for certain BCG-unresponsive patients.
  • Combination immunotherapy: Nogapendekin alfa inbakicept (Anktiva) given together with BCG is FDA-approved for certain patients with BCG-unresponsive CIS.
  • Other approaches: Additional intravesical chemotherapy combinations, newer intravesical drug-delivery systems, and clinical trials continue to emerge in this area.

The best choice depends on your specific disease, overall health, and preferences, and the landscape is evolving quickly. Ask your care team what is currently approved and appropriate for you, and consider asking whether a clinical trial is an option.

Important Precautions During BCG Treatment

Because BCG contains live bacteria, several precautions are commonly recommended. Follow your own care team’s specific instructions, which take precedence over general guidance:

  • Tell your team about immunosuppressive medications: Drugs that weaken the immune system can affect BCG and may increase the risk of systemic BCG infection. Do not start or stop medications on your own.
  • Toilet hygiene after treatment: Many programs advise disinfecting the toilet after you urinate out the BCG solution for a period after each treatment (for example, adding household bleach to the bowl, letting it sit, then flushing) to reduce any exposure to others. Follow the specific instructions you are given.
  • Hydrate well: Drink plenty of fluids after treatment unless told otherwise.
  • Avoid sexual contact briefly: Many programs advise refraining from sexual activity for a short period after each treatment; ask your team for their specific recommendation.
  • Report symptoms promptly: Persistent high fever, severe urinary symptoms, or signs of systemic illness should be reported to your medical team right away (see the emergency box above).
  • Do not receive BCG during an active infection or after traumatic catheterization: Treatment is typically postponed if you have an active urinary tract infection or if catheter placement is difficult, to reduce the risk of BCG entering the bloodstream.

Frequently Asked Questions

How painful is BCG treatment?

The catheter insertion may cause brief discomfort similar to the sensation of urinating, but the instillation of the BCG solution itself is generally not painful. The most uncomfortable part for many patients is holding the solution in the bladder, which may cause urgency and pressure. Afterward, mild burning with urination and increased frequency for a day or two are common and can often be eased with increased fluids and measures your team recommends. Ask your provider before taking any over-the-counter medication.

Can BCG cure bladder cancer?

BCG can achieve long-term remission in many patients with non-muscle-invasive bladder cancer, and some patients remain disease-free for many years. However, because bladder cancer has a high recurrence rate, the word “cure” is used cautiously. Ongoing surveillance with regular cystoscopies is essential even after a complete response, as recurrences can occur later. Your care team will set your surveillance schedule.

What happens if BCG treatment does not work?

If bladder cancer recurs or persists after adequate BCG therapy (BCG-unresponsive disease), several options exist, including radical cystectomy and FDA-approved therapies such as pembrolizumab (Keytruda), nadofaragene firadenovec (Adstiladrin), and nogapendekin alfa inbakicept (Anktiva) with BCG, as well as clinical trials. Your urologist and oncologist will discuss what is appropriate for your specific situation.

Is BCG treatment the same as the BCG tuberculosis vaccine?

BCG treatment uses the same general family of Mycobacterium bovis as the BCG tuberculosis vaccine, but the formulation and route of administration are different. For bladder cancer, BCG is instilled directly into the bladder through a catheter rather than injected under the skin. Because of the exposure involved, receiving BCG for bladder cancer can cause a positive tuberculosis skin test (PPD) afterward, so tell any clinician who orders a TB test that you have received BCG.

Why might my BCG be delayed or unavailable?

BCG has been in a documented supply shortage for years. If BCG is limited, your urologist may prioritize patients at the highest risk, adjust schedules, or discuss alternatives. Ask your care team about current availability and what it means for your plan.

Key Takeaway

BCG treatment for bladder cancer remains a leading intravesical therapy for non-muscle-invasive bladder cancer, with decades of evidence supporting its ability to reduce recurrence and lower the risk of progression. Side effects are common but usually manageable and often reflect the immune system responding — while certain warning signs, especially a high or persistent fever or signs of a body-wide infection, need urgent attention. Success depends on completing the plan your urologist designs, including maintenance therapy where recommended, and staying on the surveillance schedule. If you have been recommended BCG, discuss any concerns with your urologist so you can approach treatment with confidence.

TL;DR: BCG is an intravesical immunotherapy that activates the immune system inside the bladder and is a first-line treatment for high-risk non-muscle-invasive bladder cancer. Your urologist sets the schedule and adjusts it over time. Mild urinary and flu-like symptoms are common; a high or persistent fever or signs of a body-wide BCG infection are a medical emergency. A BCG supply shortage has been ongoing for years, and newer FDA-approved options exist for BCG-unresponsive disease.

Medical disclaimer: This article is independent, educational information and not medical advice, and it does not provide dosing. It is not a substitute for care from your urologist and oncology team. Treatment approvals, supply, and recommendations change — verify current details with your care team and authoritative sources. If you have a medical emergency, call 911 (in the U.S.) or go to the nearest emergency department.

Sources